FLAP (5-Lipoxygenase-activating protein) Inhibitors

FLAP inhibitors are a class of pharmaceutical agents that have garnered significant attention in the field of drug discovery FLAP or 5-Lipoxygenase-activating protein plays a crucial role in the production of leukotrienes which are inflammatory mediators involved in various diseases By inhibiting FLAP these inhibitors prevent the synthesis of leukotrienes thereby providing a promising approach for managing inflammatory conditions such as asthma chronic obstructive pulmonary disease (COPD) and allergic rhinitis With their potential to alleviate symptoms and improve patient outcomes FLAP inhibitors present a valuable therapeutic option in the field of pharmaceutical intervention Our company specializes in the development and production of highly effective FLAP inhibitors offering novel solutions for combating inflammatory diseases

Catalog Number	Chemical Name	CAS #	Price
EI-1096	GSK-2190915 sodium salt	1196070-26-4	Online Inquiry
EI-1133	GSK2190915	936350-00-4	Online Inquiry
EI-1136	GSK2830371	1404456-53-6	Online Inquiry
EI-1476	MK-591 sodium salt	147030-01-1	Online Inquiry
EI-1477	MK-591, Free acid	136668-42-3	Online Inquiry

Application

FLAP (5-Lipoxygenase-activating protein) inhibitors have a wide range of applications in both research and medicine In the field of research these inhibitors are used to study the role of FLAP in the production of leukotrienes inflammatory mediators involved in various diseases By blocking FLAP scientists can better understand the pathways and mechanisms underlying inflammation and develop new strategies for anti-inflammatory therapies

In medicine FLAP inhibitors have shown promise in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) where leukotrienes play a key role in airway inflammation By inhibiting FLAP these inhibitors can effectively reduce leukotriene production and alleviate symptoms

Additionally FLAP inhibitors have potential applications in the field of oncology The persistent activation of the 5-lipoxygenase pathway has been linked to the development and progression of certain cancers By inhibiting FLAP these inhibitors may be able to disrupt the production of leukotrienes involved in cancer cell growth and survival leading to potential therapeutic benefits

Overall FLAP inhibitors offer exciting possibilities for both research and therapeutic interventions with the potential to advance our understanding of inflammation and contribute to the development of novel treatments for a range of diseases

Please note that all services are for research use only. Not intended for any clinical use.

FLAP (5-Lipoxygenase-activating protein) Inhibitors